Request Demo

Last update 08 May 2025

Angiosarcoma of the Breast

Last update 08 May 2025

Basic Info

Synonyms

Angiosarcoma of Breast, Angiosarcoma of the Breast, Angiosarcoma of the breast

+ [13]

Introduction

A malignant vascular neoplasm arising from the breast.

Clinical Trials associated with Angiosarcoma of the Breast

NCT03017573

/ RecruitingNot ApplicableIIT

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.

Start Date06 Jan 2017

Sponsor / Collaborator

Institut Curie

EUCTR2012-005846-39-DE

/ Not yet recruitingPhase 2IIT

Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA) - EVA (Evaluation of Votrient in angiosarcoma)

Start Date22 Jul 2014

Sponsor / Collaborator-

100 Clinical Results associated with Angiosarcoma of the Breast

100 Translational Medicine associated with Angiosarcoma of the Breast

0 Patents (Medical) associated with Angiosarcoma of the Breast

377

Literatures (Medical) associated with Angiosarcoma of the Breast

01 Mar 2025·Virchows Archiv

TRPS1 expression in breast angiosarcoma

Article

Author: Papp, Eszter ; Kulka, Janina ; Pancsa, Tamás ; Cserni, Gábor ; Schubert, Anna ; Kuthi, Levente ; Varga, Linda ; Kovács, Kristóf Attila ; Chien, Yi-Che Chang ; Kálmán, Endre ; Almási, Szintia ; Pósfai, Boglárka

AbstractAngiosarcoma (AS) of the breast, a rare mesenchymal neoplasm, exhibits distinct forms based on etiological and genetic features. While cases with typical clinical presentation and morphology allow for a straightforward diagnosis, challenges arise when clinical data are scarce, diagnostic material is limited, or morphological characteristics overlap with other tumors, including undifferentiated carcinomas. The trichorhinophalangeal syndrome protein 1 (TRPS1), once regarded as highly specific for breast carcinomas, now faces doubts regarding its reliability. This study explores TRPS1 expression in breast AS. Our investigation revealed that 60% of AS cases displayed TRPS1 labeling, contrasting with the 40% lacking expression. Scoring by four independent readers established a consensus, designating 12/35 ASs as unequivocally TRPS1-positive. However, uncertainty surrounded nine further cases due to a lack of reader agreement (being substantial as reflected by a kappa value of 0.76). These findings challenge the perceived specificity of TRPS1, shedding light on its presence in a noteworthy proportion of breast ASs. Consequently, the study underscores the importance of a comprehensive approach in evaluating breast ASs and expands the range of entities within the differential diagnosis associated with TRPS1 labeling.

25 Jan 2025·Cureus

Secondary Breast Angiosarcoma Five Years After Radiation Therapy for Ductal Carcinoma In Situ

Article

Author: Brown, Pierpont ; Wyer, Abigayle ; Grabill, Nathaniel ; Louis, Mena ; Strom, Priscilla

Radiation-induced angiosarcoma (RIAS) of the breast is a rare and aggressive malignancy that emerges as a late complication of radiation therapy for primary breast cancer. We present the case of a 56-year-old woman with a history of high-grade ductal carcinoma in situ (DCIS) of the breast, previously treated with lumpectomy, sentinel lymph node biopsy, radiation therapy, and anastrozole. Five years after treatment, she developed new skin changes on her breast, including bruising and blistering following tanning bed use. Imaging studies showed diffuse skin thickening without discrete masses or lymphadenopathy. Biopsies confirmed the diagnosis of angiosarcoma. An extended mastectomy with wide surgical margins was performed. Pathological examination confirmed angiosarcoma with negative margins and no lymph node involvement. Additional excisions were undertaken to achieve 3 cm gross margins to ensure complete tumor removal due to the aggressive nature of the tumor. Patients presenting with new skin changes in previously irradiated areas, even many years after treatment, require careful evaluation. Nonspecific clinical and imaging findings necessitate prompt biopsy for accurate diagnosis. Surgical excision with wide margins remains the primary treatment modality, but standardized guidelines are lacking due to the rarity of RIAS. A multidisciplinary approach involving surgical oncology, pathology, radiology, and reconstructive surgery is essential for optimal patient management. Educating patients about potential late complications of radiation therapy and advising against additional risk factors, such as ultraviolet 2 exposure from tanning beds, are important. Further research is needed to establish evidence-based guidelines for the diagnosis, treatment, and follow-up of RIAS.

01 Dec 2024·European Journal of Surgical Oncology

Timeline of surgery in localized angiosarcoma of the breast: Improving outcome following multidisciplinary treatment optimization

Article

Author: Gronchi, Alessandro ; Folli, Secondo ; Cortinovis, Umberto ; Vingiani, Andrea ; Casali, Paolo G ; Stacchiotti, Silivia ; Collini, Paola ; Fiore, Marco ; Allajbej, Albina ; Listorti, Chiara ; Palassini, Elena ; Sangalli, Claudia ; Mariani, Luigi ; Casali, Paolo G. ; Gennaro, Massimiliano

INTRODUCTIONPrimary (PAS) and radiation-associated angiosarcomas (RAAS) of the breast are rare tumors of vascular origin with poor survival. In this retrospective cohort study, we aimed to assess the impact of multidisciplinary treatment optimization on the prognosis of patients who underwent surgery at a national referral center.MATERIALS AND METHODSCases of operable angiosarcoma of the breast evaluated by a multidisciplinary team including surgeons, medical oncologists and radiation oncologists expert in the field and treated from January 2012 to January 2023 were retrieved from a prospectively maintained database. The outcomes of three treatment groups, defined by the timing of surgery in relation to adjuvant and neoadjuvant therapies, were compared.RESULTSFifty-nine patients with operable angiosarcomas of the breast (49 RAAS and 10 PAS) were retrospectively identified. The five-year overall survival was 85.2 % (95 % CI 73.9-98.2) and event-free survival was significantly better in patients with grade 1 than those with grade 2 or 3 tumors. Patients receiving neoadjuvant chemotherapy had significantly better outcomes than those treated with primary surgery. Pathological complete response was significantly higher in patients receiving neoadjuvant radiotherapy after neoadjuvant chemotherapy, and a trend towards better distant-disease-free survival was found for patients with complete response at time of surgery.CONCLUSIONSOptimization of angiosarcoma treatment based on specialized, multidisciplinary assessment regarding the type and timing of surgery and the use of neoadjuvant chemoradiotherapy can improve outcomes. The findings of this study support the use of neoadjuvant chemotherapy as well as adjuvant and neoadjuvant radiotherapy in clinical practice.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Angiosarcoma of the Breast

Basic Info

Related

Analysis